226 results found.

Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Onc Clinical Trial using AMG 232

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors.
AMG 232

Hematologic Disease, Hematologic Neoplasm, or Pancytopenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies.

Solid Tumors, or Acute Kidney Injury Clinical Trial using Mesenchymal stromal cell infusion

Mario Negri Institute for Pharmacological Research - Recruiting 18 years to 80 years.
- Ex-Vivo Expanded Mesenchymal Stem Cells To Repair The Kidney And Improve Function In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers.
Mesenchymal stromal cell infusion

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Neoplasms Clinical Trial using BI 860585; exemestane; paclitaxel

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours.
BI 860585; exemestane; paclitaxel

Neoplasms Clinical Trial using MPDL3280A; bevacizumab [Avastin]; FOLFOX; carboplatin; paclitaxel; pemetrexed; nab-paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors.
MPDL3280A; bevacizumab [Avastin]; FOLFOX; carboplatin; paclitaxel; pemetrexed; nab-paclitaxel

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma.
veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

Solid Tumors Clinical Trial using thioureidobutyronitrile

Cellceutix Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors.
thioureidobutyronitrile

Cancer, or Solid Tumor Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors.
MK-3475

HIV Infection, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Solid Cancers Clinical Trial using letrozole; fulvestrant; GDC-0032

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer.
letrozole; fulvestrant; GDC-0032

Solid Tumour Clinical Trial using GDC-0994

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors.
GDC-0994

Neoplasms Clinical Trial using MEHD7945A; cobimetinib

Genentech - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A and GDC-0973 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH MUTANT KRAS.
MEHD7945A; cobimetinib

Non-Hodgkin's Lymphoma, Solid Cancers Clinical Trial using GDC-0980

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma.
GDC-0980

Neoplasms Clinical Trial using GDC-0973; GDC-0068

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors.
GDC-0973; GDC-0068

Lymphoma, Solid Tumour Clinical Trial using GDC-0575; gemcitabine

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma.
GDC-0575; gemcitabine

Solid Cancers Clinical Trial using paclitaxel; docetaxel; GDC-0068; mFOLFOX6; enzalutamide

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors.
paclitaxel; docetaxel; GDC-0068; mFOLFOX6; enzalutamide

Neoplasms Clinical Trial using BAY1125976

Bayer - Recruiting 18 years or older.
- A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors.
BAY1125976

Osteosarcoma Clinical Trial using Tissue Procurement

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors.
Tissue Procurement

Solid Cancers Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies.
MPDL3280A

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

Solid Tumors, Melanoma, or Metastatic Colorectal Cancer Clinical Trial using CEP-32496

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal Cancer With BRAF Mutation in Phase 2.
CEP-32496

Solid Tumors Clinical Trial using CEP-37440

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors.
CEP-37440

EGFR Positive Solid Tumors Clinical Trial using IMGN289

ImmunoGen, Inc. - Recruiting 18 years or older.
- A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors.
IMGN289

Hematologic Malignancies, or Solid Tumors Clinical Trial using omacetaxine mepesuccinate

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors.
omacetaxine mepesuccinate

Advanced Solid Tumors Clinical Trial using ABT-165; paclitaxel; FOLFIRI

AbbVie - Recruiting 18 years or older.
- A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors.
ABT-165; paclitaxel; FOLFIRI

Oncology, BRCA Mutated, High Grade Serous Ovarian Cancer, or BRCA Clinical Trial using Veliparib

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors.
Veliparib

Cholangiocarcinoma, Chondrosarcoma, Glioma, or Advanced Solid Tum Clinical Trial using AG-120

Agios Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation.
AG-120

Tumor or Lymphoma Clinical Trial using JNJ-42756493

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
JNJ-42756493

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors..
PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Advanced Solid Tumors Clinical Trial using TAS-102 with a light tracer dose of [14C]FTD; TAS-102 with a light tracer dose of [14C] TPI; TAS-102 tablets

Taiho Pharma USA, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors.
TAS-102 with a light tracer dose of [14C]FTD; TAS-102 with a light tracer dose of [14C] TPI; TAS-102 tablets

Advanced Solid Tumors (Excluding Breast Cancer) Clinical Trial using TAS-102 tablets; TAS-102 oral solution

Taiho Pharma USA, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI.
TAS-102 tablets; TAS-102 oral solution

Neoplasms Clinical Trial using zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase Ia/Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotininb (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-positive Solid Tumors of Ephitelian Cell Origin.
zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Neoplasms Clinical Trial using RO5509554; paclitaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors..
RO5509554; paclitaxel

Neoplasms Clinical Trial using RO5503781; posaconazole

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTIPLE-CENTER, OPEN-LABEL CLINICAL PHARMACOLOGY STUDY WITH RO5503781, AN MDM2 ANTAGONIST, IN PATIENTS WITH SOLID TUMORS TO DETERMINE: PART 1 ONE-SEQUENCE, 2-PERIOD CROSSOVER DESIGN TO INVESTIGATE THE EFFECT OF POSACONAZOLE, A STRONG CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RO5503781 PART 2 A RANDOMIZED, SINGLE DOSE, 3 PERIOD CROSSOVER DESIGN TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO NEW RO5503781 TABLET FORMULATIONS FOLLOWING ORAL ADMINISTRATION.
RO5503781; posaconazole

Neoplasms Clinical Trial using RO5429083

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors.
RO5429083

Malignant Solid Neoplasms Clinical Trial using Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD)

Centre Leon Berard - Recruiting 18 years or older.
- A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors.
Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD)

Advanced Solid Tumors Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors.
LEE011

Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Clinical Trial using TKI258

Novartis - Recruiting 18 years or older.
- A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer.
TKI258

Solid Tumors, or Pregnancy Clinical Trial using Data Collection

M.D. Anderson Cancer Center - Recruiting N/A or older.
- Collection of Outcomes Data for Pregnant Patients With Cancer.
Data Collection

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of Oral Calcitriol With Fixed Dose of Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors.
calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Solid Tumors, or Metastatic Disease Clinical Trial using Histological biopsy procedure

UMC Utrecht - Recruiting 18 years or older.
- Protocol to Obtain Tumor Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer to Improve Selection for Clinical Trials. (CPCT - 05 Biopsy Protocol Patient Selection).
Histological biopsy procedure

Neoplasms Clinical Trial using Refametinib (BAY86-9766); Gemcitabine

Bayer - Recruiting 18 years or older.
- A Multi-center, Phase Ib Study of MEK (Mitogen Activated Protein Kinase/ERK Kinase) Inhibitor BAY86-9766 Plus Gemcitabine in Asian Patients With Advanced or Refractory Solid Tumors.
Refametinib (BAY86-9766); Gemcitabine

Advanced Solid Tumors,, or Metastatic Solid Tumors Clinical Trial using BGJ398; BYL719

Novartis - Recruiting 18 years or older.
- A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors.
BGJ398; BYL719

Cancer, or Advanced Solid Tumors Clinical Trial using Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)

VU University Medical Center - Recruiting 18 years or older.
- Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies..
Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)

Solid Tumor, or Non-small Cell Lung Cancer Clinical Trial using MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Merck Sharp & Dohme Corp. - Recruiting 20 years or older.
- A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Cisplatin/Pemetrexed or Carboplatin/Paclitaxel in Subjects With Advanced Non-Small Cell Lung Cancer.
MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, or Desmoplastic Small Clinical Trial using Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 35 years.
- A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias.
Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

Neoplasms, or Lymphoma Clinical Trial using MK-1775

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Single-agent MK-1775, a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors.
MK-1775

Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Brea Clinical Trial using BMN 673

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations.
BMN 673

Neoplasms Clinical Trial using 5-Fluoro-2-Deoxycytidine; Tetrahydrouridine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.
5-Fluoro-2-Deoxycytidine; Tetrahydrouridine

Solid Tumors Clinical Trial using Bevacizumab; Dasatinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors.
Bevacizumab; Dasatinib

Lymphomas, or Solid Tumors Clinical Trial using TRC 102; Temozolomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas.
TRC 102; Temozolomide

Solid Tumors, Brain Tumors, Sarcoma, Wilm's Tumor, or Rhabdomyosa Clinical Trial using NK cellular therapy; rhIL-15

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 29 years.
- A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors.
NK cellular therapy; rhIL-15

Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant, or Clinical Trial using NHS-IL-12

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- First In-Human Phase I Trial of NHS-IL12 in Subjects With Metastatic Solid Tumors.
NHS-IL-12

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using vismodegib; sirolimus; positron emission tomography; computed tomography; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18

Mayo Clinic - Recruiting 18 years or older.
- Phase I Trial of The Combination of Vismodegib and Sirolimus.
vismodegib; sirolimus; positron emission tomography; computed tomography; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18

Solid Tumors Clinical Trial using Proton Therapy

Proton Collaborative Group - Recruiting N/A or older.
- Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Proton Therapy.
Proton Therapy

Neoplasms, or Lymphoma Clinical Trial using LMP 400; LMP 776

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas.
LMP 400; LMP 776

Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors.

Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, or Brain Tumo Clinical Trial using plerixafor

Sanofi - Recruiting 1 year to 18 years.
- A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to <18 Years, With Solid Tumours Eligible for Autologous Transplants..
plerixafor

Sarcoma, Stomach Neoplasms, or Neoplasms Clinical Trial using Pazopanib; ARQ 197

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors.
Pazopanib; ARQ 197

Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, or Rena Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies.

Neoplasms Clinical Trial using Temozolomide; Everolimus; Carboplatin; Trametinib DMSO; ABT-888; MK-1775

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors.
Temozolomide; Everolimus; Carboplatin; Trametinib DMSO; ABT-888; MK-1775

Neuroblastoma;, Rhabdomyosarcoma;, Ewing's Sarcoma;, Ewing's Tumo Clinical Trial using nab-paclitaxel

Celgene Corporation - Recruiting 6 Months to 21 years.
- A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
nab-paclitaxel

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors.
DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis

Neoplasm Malignant Clinical Trial using SAR566658

Sanofi - Recruiting 18 years or older.
- Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Adult Patients With CA6-Positive and Refractory Solid Tumors.
SAR566658

Advanced Solid Tumors Clinical Trial using TAS-114 + S-1

Taiho Pharmaceutical Co., Ltd. - Recruiting 20 years or older.
- A Phase 1 Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors.
TAS-114 + S-1

Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic T Clinical Trial using alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

St. Jude Children's Research Hospital - Recruiting 2 years to 21 years.
- A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas.
alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

Neoplasms Clinical Trial using RO6895882

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION, PHASE I STUDY WITH AN EXPANSION PHASE, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, CONSISTING OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
RO6895882

Neoplasms Clinical Trial using RO5520985

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors..
RO5520985

Solid Tumors, or Advanced Cancer Clinical Trial using Anastrozole; Bevacizumab; Everolimus; Sorafenib; Erlotinib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance.
Anastrozole; Bevacizumab; Everolimus; Sorafenib; Erlotinib

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using veliparib; mitomycin C; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair.
veliparib; mitomycin C; laboratory biomarker analysis

Solid Tumors, Lymphoma, or Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib; Gefitinib

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies.
LY2875358; Erlotinib; Gefitinib

Malignant Solid Tumour, or Gastroesophageal Cancer Clinical Trial using Tivantinib; FOLFOX

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II).
Tivantinib; FOLFOX

Solid Tumors Clinical Trial using Whey protein; Nutritional counseling

IRCCS Policlinico S. Matteo - Recruiting 18 years or older.
- Whey Protein Supplementation in Malnourished Cancer Patients: a Randomized, Controlled Trial.
Whey protein; Nutritional counseling

PTCH1 or SMO Activated Solid and Hematologic Tumors Clinical Trial using LDE225

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors.
LDE225

Cancer Clinical Trial using GSK1120212; Docetaxel + GSK1120212; Erlotinib + GSK1120212; Pemetrexed + GSK1120212; Carboplatin + GSK1120212; Nab-paclitaxel + GSK1120212; Gemcitabine + GSK1120212; Everolimus + GSK1120212

GlaxoSmithKline - Recruiting 18 years or older.
- MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors and Leukemia.
GSK1120212; Docetaxel + GSK1120212; Erlotinib + GSK1120212; Pemetrexed + GSK1120212; Carboplatin + GSK1120212; Nab-paclitaxel + GSK1120212; Gemcitabine + GSK1120212; Everolimus + GSK1120212

Neoplasms, or Lymphoma Clinical Trial using Part 1: JNJ-42756493; Part 2: JNJ-42756493

Janssen Research & Development, LLC - Recruiting 20 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
Part 1: JNJ-42756493; Part 2: JNJ-42756493

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN9708

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1 Study of [14C]-MLN9708 to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas.
MLN9708

Thrombocytopaenia Clinical Trial using Eltrombopag olamine; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin.
Eltrombopag olamine; Placebo

Neoplasm Malignant Clinical Trial using Cabazitaxel (XRP6258)

Sanofi - Recruiting 18 years or older.
- Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment.
Cabazitaxel (XRP6258)

Advanced Solid Tumors, or Lymphomas Clinical Trial using Camptothecin-20-O-Propionate Hydrate (CZ48)

New Mexico Cancer Care Alliance - Recruiting 18 years or older.
- Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma.
Camptothecin-20-O-Propionate Hydrate (CZ48)

Fallopian Tube, Primary Peritoneal Cancer, or Solid Tumors (eg Br Clinical Trial using ABT-767

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
ABT-767

Solid Tumors, or Hepatic Dysfunction Clinical Trial using Trametinib

University Health Network, Toronto - Recruiting 18 years or older.
- A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction.
Trametinib

Stomach Neoplasms Clinical Trial using AMG 337

Amgen - Recruiting 18 years or older.
- A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors.
AMG 337

Ewing Sarcoma, or Sarcoma Clinical Trial using Mithramycin

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Phase I/II Trial of Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript (Phase II).
Mithramycin

Solid Tumors, Lymphoma, or Multiple Myeloma Clinical Trial using CS-7017 and Bexarotene

Georgetown University - Recruiting 18 years or older.
- A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene.
CS-7017 and Bexarotene

Advanced Solid Tumors Clinical Trial using Lapatinib and bortezomib

Georgetown University - Recruiting 18 years or older.
- A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies.
Lapatinib and bortezomib

Sarcoma, Solid Tumors, Pulmonary Metastases, Lung Metastases, Ost Clinical Trial using Aerosol IL-2; Symptom Assessment

M.D. Anderson Cancer Center - Recruiting 12 years or older.
- Phase I/II Study of Aerosol Interleukin-2 for Pulmonary Metastases.
Aerosol IL-2; Symptom Assessment

Melanoma, Metastatic Melanoma, or Solid Tumor Clinical Trial using MLN2480

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma.
MLN2480

Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Adva Clinical Trial using FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Amgen - Recruiting 18 years or older.
- A Phase 2 Open Label Extension Study of Conatumumab and AMG 479.
FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Neoplasms Clinical Trial using BAY1163877

Bayer - Recruiting 18 years or older.
- An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors.
BAY1163877

Solid Tumors Clinical Trial using axitinib

Pfizer - Recruiting N/A or older.
- Continuing Access To The Tyrosine Kinase Inhibitor Of VEGFR 2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials.
axitinib

Solid Tumors, Cancer, or NSCLC Clinical Trial using cabozantinib capsules; cabozantinib tablets

Exelixis - Recruiting 20 years or older.
- Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors.
cabozantinib capsules; cabozantinib tablets

Oncology Clinical Trial using BAY94-9343; BAY94-9343 (Expansion); BAY94-9343 (1.8 mg/kg); BAY94-9343 (2.2 mg/kg)

Bayer - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors.
BAY94-9343; BAY94-9343 (Expansion); BAY94-9343 (1.8 mg/kg); BAY94-9343 (2.2 mg/kg)

Solid Tumors Clinical Trial using MLN4924 and Docetaxel; MLN4924 + Paclitaxel + Carboplatin (Arm 2); MLN4924 + Gemcitabine (Arm 3)

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors.
MLN4924 and Docetaxel; MLN4924 + Paclitaxel + Carboplatin (Arm 2); MLN4924 + Gemcitabine (Arm 3)

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN8237

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas.
MLN8237

Solid Tumors, or Lymphoma Clinical Trial using alisertib; esomeprazole; rifampin

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas.
alisertib; esomeprazole; rifampin

Neoplasms Clinical Trial using Cobimetinib; MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors.
Cobimetinib; MPDL3280A

Breast Neoplasms Clinical Trial using Sorafenib (Nexavar, BAY43-9006); Eribulin

Bayer - Recruiting 18 years or older.
- A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors.
Sorafenib (Nexavar, BAY43-9006); Eribulin

Advanced Malignant Solid Tumors Clinical Trial using MLN7243

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors.
MLN7243

BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, or Unspecified Ad Clinical Trial using veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1 Trial of ABT-888 and SCH727965 Without or With Carboplatin in Patients With Advanced Solid Tumors.
veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors.
dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using dabrafenib; pazopanib hydrochloride; Correlative studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors.
dabrafenib; pazopanib hydrochloride; Correlative studies

Neuroblastoma Clinical Trial using 3F8 Monoclonal Antibody Combined with Interleukin-2

Memorial Sloan-Kettering Cancer Center - Recruiting 13 Months or older.
- Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors.
3F8 Monoclonal Antibody Combined with Interleukin-2

Advanced Solid Tumors Clinical Trial using MEDI4736

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Japanese Patients With Advanced Solid Tumors.
MEDI4736

Solid Tumors Clinical Trial using OMP-18R5

OncoMed Pharmaceuticals, Inc. - Recruiting 18 years to 90 years.
- A Phase 1 Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors.
OMP-18R5

Advanced Solid Tumor, or Lymphomas Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011

Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Clinical Trial using veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy.
veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

Solid Tumors Clinical Trial using OMP-54F28

OncoMed Pharmaceuticals, Inc. - Recruiting 18 years to 90 years.
- A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors.
OMP-54F28

Solid Tumors Clinical Trial using MK-8242

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors.
MK-8242

Solid Tumors Clinical Trial using LCL161; Paclitaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors.
LCL161; Paclitaxel

Various Advanced Cancer Clinical Trial using BMS-986115

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors.
BMS-986115

Solid Tumors Clinical Trial using Sym004

Merck KGaA - Recruiting 20 years or older.
- A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors.
Sym004

KRAS Mutated Colorectal Adenocarcinoma, Metastatic Pancreatic Ade Clinical Trial using MEK162 + AMG 479

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors.
MEK162 + AMG 479

Cancer, Advanced Solid Tumors Clinical Trial using BBI503

Boston Biomedical, Inc - Recruiting 18 years or older.
- A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors.
BBI503

Advanced Solid Tumor, or Lymphoma Clinical Trial using DS-3032

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas.
DS-3032

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using nanosomal docetaxel lipid suspension; pharmacological study

USC/Norris Comprehensive Cancer Center - Recruiting 18 years to 64 years.
- An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors.
nanosomal docetaxel lipid suspension; pharmacological study

Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Can Clinical Trial using DCVax-Direct

Northwest Biotherapeutics - Recruiting 18 years to 75 years.
- A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS.
DCVax-Direct

Solid Tumors Clinical Trial using uncaria tomentosa (cat's claw)

Faculdade de Medicina do ABC - Recruiting 18 years or older.
- Phase II Clinical Trial of Uncaria Tomentosa (Cat's Claw) in Patients With Advanced Solid Tumors.
uncaria tomentosa (cat's claw)

Recurrent or Refractory Solid Tumors, or CNS Malignancies Clinical Trial using Bevacizumab; Everolimus

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- A Phase I Trial of RAD001 (Everolimus) and Avastin(R) (Bevacizumab) in Children With Recurrent Solid Tumors.
Bevacizumab; Everolimus

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma Clinical Trial using Urelumab (BMS-663513)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL).
Urelumab (BMS-663513)

Cancer Clinical Trial using Paclitaxel; 5-Fluorouracil (5-FU); Carboplatin; Leucovorin; Irinotecan; BMS-906024

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors.
Paclitaxel; 5-Fluorouracil (5-FU); Carboplatin; Leucovorin; Irinotecan; BMS-906024

CANCER, NOS Clinical Trial using Lirilumab; Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors.
Lirilumab; Ipilimumab

Advanced or Metastatic Solid Tumors, or Advanced or Metastatic Br Clinical Trial using Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

University of Utah - Recruiting 18 years or older.
- A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer.
Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

CANCER,NOS Clinical Trial using Lirilumab; Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Patients With Advanced Solid Tumors.
Lirilumab; Nivolumab

Neoplasms by Site Clinical Trial using BMS-986016; BMS-936558

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors.
BMS-986016; BMS-936558

Solid Tumor and Hematologic Malignancies Clinical Trial using MEK162

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors.
MEK162

Solid Tumors and Non-Hodgkin's Lymphoma Clinical Trial using LY2780301; Gemcitabine

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer.
LY2780301; Gemcitabine

Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosar Clinical Trial using MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

Merrimack Pharmaceuticals - Recruiting 12 Months to 20 years.
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors.
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

Solid Tumors Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors.
INC280

Metastatic Solid Tumors Clinical Trial using MLN1117

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease.
MLN1117

Hepatic Complications, Renal Failure, or Unspecified Adult Solid Clinical Trial using dabrafenib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction.
dabrafenib; pharmacological study; laboratory biomarker analysis

Tumor, Solid Clinical Trial using MK-8353

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (Formerly SCH 900353) in Subjects With Advanced Solid Tumors (Protocol No. 001 (Formerly P06203)).
MK-8353

Solid Tumors, or Lymphoma Clinical Trial using PU-H71

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma.
PU-H71

Advanced Solid Tumors Clinical Trial using MP-3549.1

Mallinckrodt - Recruiting 18 years or older.
- A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MP-3549.1 in Subjects With Advanced Solid Tumors.
MP-3549.1

Neoplasms Clinical Trial using IMC-3C5

Eli Lilly and Company - Recruiting 18 years or older.
- Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.
IMC-3C5

Solid Tumor, or Anaplastic Thyroid Cancer Clinical Trial using Cisplatin and Crolibulin; Cisplatin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC).
Cisplatin and Crolibulin; Cisplatin

Breast Cancer, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using positron emission tomography/computed tomography; fludeoxyglucose F 18; PET/MRI; gadopentetate dimeglumine; questionnaire administration

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Positron Mammographic Imaging (PMI).
positron emission tomography/computed tomography; fludeoxyglucose F 18; PET/MRI; gadopentetate dimeglumine; questionnaire administration

Neoplasms, Brain Clinical Trial using Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

GlaxoSmithKline - Recruiting 1 Month to 17 years.
- Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation Positive Solid Tumors.
Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

Cancer Clinical Trial using GSK2256098

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects With Solid Tumors.
GSK2256098

Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Ad Clinical Trial using ADI-PEG 20

Polaris Group - Recruiting 18 years or older.
- Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies.
ADI-PEG 20

Tumors Metastatic to Brain, or Unspecified Adult Solid Tumor Clinical Trial using stereotactic radiosurgery; quality-of-life assessment; cognitive assessment

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Dose Escalation for Larger Brain Metastases: Phase I/II Study.
stereotactic radiosurgery; quality-of-life assessment; cognitive assessment

Advanced Solid Tumor Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors.
INC280

Neoplasms Clinical Trial using Regorafenib (Stivarga, BAY73-4506); Cetuximab (ERBITUX)

Bayer - Recruiting 18 years or older.
- A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment.
Regorafenib (Stivarga, BAY73-4506); Cetuximab (ERBITUX)

Neoplasm Malignant Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma.
SAR245409

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Solid Tumors Clinical Trial using ASP5878

Astellas Pharma Inc - Recruiting 20 years or older.
- An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors.
ASP5878

Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medul Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 18 years.
- A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Hormone Receptor-Positive Breast, Gynecologic, Desmoid, or Hormon Clinical Trial using z-Endoxifen; [(18)F] Fluoroestradiol

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors.
z-Endoxifen; [(18)F] Fluoroestradiol

Colorectal Neoplasms, Colorectal Carcinoma, or Colorectal Tumors Clinical Trial using ISIS 183750; Irinotecan

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer.
ISIS 183750; Irinotecan

Advanced Solid Tumor Clinical Trial using LDE225; Wafarin; Bupropion

Novartis - Recruiting 18 years or older.
- A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors.
LDE225; Wafarin; Bupropion

Neoplasms Clinical Trial using PF-06263507

Pfizer - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors.
PF-06263507

Malignant Solid Tumor - Malignant Nervous System Neoplasm Clinical Trial using Cabazitaxel (XRP6258)

Sanofi - Recruiting 2 years to 18 years.
- A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System.
Cabazitaxel (XRP6258)

Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, or Esophag Clinical Trial using GS-5745 monotherapy and in combination with chemotherapy

Gilead Sciences - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors.
GS-5745 monotherapy and in combination with chemotherapy

Hematologic Cancers, Solid Tumors, or Metastatic Cancer Clinical Trial using Crizotinib

UNICANCER - Recruiting 1 year or older.
- AcS‚ CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug..
Crizotinib

Solid Tumors, or Non-small Cell Lung Cancer Clinical Trial using oral 5-azacitidine in combination with romidepsin

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer.
oral 5-azacitidine in combination with romidepsin

Solid Tumor Malignancies Clinical Trial using Clostridium novyi-NT spores

BioMed Valley Discoveries, Inc - Recruiting 18 years or older.
- Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies.
Clostridium novyi-NT spores

Cancer Clinical Trial using GSK2256098; Trametinib

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors.
GSK2256098; Trametinib

Cancer Clinical Trial using GSK2849330

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors.
GSK2849330

Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Clinical Trial using Veliparib (ABT-888); Placebo

AbbVie - Recruiting 18 years or older.
- A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors.
Veliparib (ABT-888); Placebo

Neoplasms Clinical Trial using 4 mg/kg Onartuzumab (MetMAb); 15 mg/kg Onartuzumab (MetMAb); 30 mg/kg Onartuzumab (MetMAb)

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.
4 mg/kg Onartuzumab (MetMAb); 15 mg/kg Onartuzumab (MetMAb); 30 mg/kg Onartuzumab (MetMAb)

Neoplasms Clinical Trial using Afatinib; docetaxel; gemcitabine

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of Once Daily Oral Treatment Using Afatinib (BIBW2992) Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors..
Afatinib; docetaxel; gemcitabine

Neoplasm Metastasis Clinical Trial using LY2940680

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors.
LY2940680

Solid Tumors, Hematologic Malignancies, or Hepatic Impairment Clinical Trial using Carfilzomib

Onyx Pharmaceuticals - Recruiting 18 years or older.
- An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment.
Carfilzomib

Solid Tumors, or Non-small Cell Lung Carcinoma Clinical Trial using DS-2248

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors.
DS-2248

Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm Clinical Trial using Alisertib; Pazopanib

University of Illinois at Chicago - Recruiting 18 years or older.
- Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors.
Alisertib; Pazopanib

Solid Tumors With Oligometastatic Spread Clinical Trial using Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance

University Health Network, Toronto - Recruiting 18 years or older.
- A Phase II Study on the Toxicity and Efficacy of a Normal Tissue Tolerance Adapted, 5 Fraction Stereotactic Body Radiation Therapy (SBRT) Regimen, for Extra-Cranial Oligometastases.
Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance

Solid Tumors Clinical Trial using MEDI4736; Tremelimumab

Ludwig Institute for Cancer Research - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors.
MEDI4736; Tremelimumab

Advanced Solid Tumors Clinical Trial using PRI-724

Prism Pharma Co., Ltd. - Recruiting 18 years or older.
- A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors.
PRI-724

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using methoxyamine; temozolomide; DNA analysis; laboratory biomarker analysis; pharmacological study

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumors.
methoxyamine; temozolomide; DNA analysis; laboratory biomarker analysis; pharmacological study

Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, or Malign Clinical Trial using 2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

to-BBB technologies B.V. - Recruiting 18 years or older.
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

Advanced Cancers, or Solid Tumors Clinical Trial using Erlotinib; Pralatrexate

M.D. Anderson Cancer Center - Recruiting 12 years or older.
- A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer.
Erlotinib; Pralatrexate

Diffuse Large B Cell Lymphoma Clinical Trial using E7438

Eisai Inc. - Recruiting 18 years or older.
- An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas.
E7438

Solid Tumors Clinical Trial using E7389-LF

Eisai Inc. - Recruiting 18 years or older.
- An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors.
E7389-LF

Solid Tumors Clinical Trial using ARQ 761

University of Texas Southwestern Medical Center - Recruiting 18 years or older.
- A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors.
ARQ 761

Advanced Cancers, or Lymphoma Clinical Trial using NC-4016

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma.
NC-4016

Neoplasms, or Hematologic Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members.

Solid Tumors, or Relapsed/Refractory Sarcomas Clinical Trial using Vorinostat and Etoposide

Memorial Sloan-Kettering Cancer Center - Recruiting 4 years to 21 years.
- A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors.
Vorinostat and Etoposide

Glioblastoma Multiforme Clinical Trial using Bevacizumab; BKM120

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II).
Bevacizumab; BKM120

Advanced Solid Tumors, Kidney Disease, or Renal Impairment Clinical Trial using AMG 386 + Paclitaxel; AMG 386

Amgen - Recruiting 18 years or older.
- An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function.
AMG 386 + Paclitaxel; AMG 386

Major Advanced Solid Tumors Other Than Colorectal Clinical Trial using PM01183

PharmaMar - Recruiting 18 years or older.
- Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 on Days 1 and 8 Every Three Weeks (q3wk) in Non-Colorectal Cancer (Non-CRC) Patients.
PM01183

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Morphotek - Recruiting 13 Months to 21 years.
- Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors.
anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Colorectal Cancer, or Head and Neck Cancer Clinical Trial using Nilotinib + Cetuximab

Georgetown University - Recruiting 18 years or older.
- A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab.
Nilotinib + Cetuximab

Endometrial Adenocarcinomas, Neuroendocrine Tumors, or Small-cell Clinical Trial using lurbinectedin (PM01183); Doxorubicin

PharmaMar - Recruiting 18 years to 75 years.
- Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors.
lurbinectedin (PM01183); Doxorubicin

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial using tivantinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 21 years.
- A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors.
tivantinib; pharmacological study; laboratory biomarker analysis

Solid Tumors Clinical Trial using nesvacumab (REGN910/ SAR307746); aflibercept (ziv-aflibercept)

Regeneron Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies.
nesvacumab (REGN910/ SAR307746); aflibercept (ziv-aflibercept)

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors.
veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

Solid Tumors Clinical Trial using patritumab

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors.
patritumab

Lung Cancer, Non Small Cell Lung Cancer, or Solid Tumors Clinical Trial using Stereotactic Body Radiation

New Mexico Cancer Care Alliance - Recruiting 18 years or older.
- INST 0810: Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung.
Stereotactic Body Radiation

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma.
riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

Solid Tumors Clinical Trial using MSB0010718C

Merck KGaA - Recruiting 20 years or older.
- A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer.
MSB0010718C

Solid Tumors, Untreated Pancreatic Adenocarcinoma, Pancreatic Can Clinical Trial using PLX7486-TsOH; gemcitabine; nab-Paclitaxel

Plexxikon - Recruiting 18 years or older.
- A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent and in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Solid Tumors.
PLX7486-TsOH; gemcitabine; nab-Paclitaxel

At This Time, All Cohorts Are Closed to Enrollment With the Excep Clinical Trial using PLX3397

Plexxikon - Recruiting 18 years or older.
- A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology.
PLX3397

Refractory Solid Tumors, or Leukemia Clinical Trial using Bevacizumab; Sorafenib; Cyclophosphamide

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia.
Bevacizumab; Sorafenib; Cyclophosphamide

Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, o Clinical Trial using CTLA-4 Antibody; Hypofractionated Radiotherapy

Western Regional Medical Center - Recruiting 18 years or older.
- A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST).
CTLA-4 Antibody; Hypofractionated Radiotherapy

Solid Tumours Clinical Trial using dabrafenib; trametinib

GlaxoSmithKline - Recruiting 20 years or older.
- A Japanese Open-label Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of GSK2118436 and GSK1120212 Combination Therapy in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) and BRAF V600E/K Mutation Positive Cutaneous Melanoma (Phase II Part)..
dabrafenib; trametinib

Solid Tumor Clinical Trial using ARQ 087

ArQule - Recruiting 18 years or older.
- A Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors.
ARQ 087

Advanced Solid Tumors Clinical Trial using ARQ 197 as monotherapy or in combination with other drug(s)

ArQule - Recruiting N/A or older.
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols.
ARQ 197 as monotherapy or in combination with other drug(s)

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using alisertib; gemcitabine

University of California, Davis - Recruiting 18 years or older.
- Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer.
alisertib; gemcitabine

Advanced Cancers (Solid Tumors) Clinical Trial using GL-ONC1

Genelux Corporation - Recruiting 18 years or older.
- Phase I Study of the Safety, Tolerability,and Tumor-Specific Replication of the Intravenous Administration of Green Fluorescent Protein Encoded Genetically Engineered Attenuated Vaccinia Virus, GL-ONC1, in Patients With Advanced Solid Organ Cancers..
GL-ONC1

Advanced Solid Tumours Clinical Trial using WX-037; WX-554

Wilex - Recruiting 18 years or older.
- A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors.
WX-037; WX-554

Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyo Clinical Trial using Metronomic Cyclophosphamide; Thalidomide

Washington University School of Medicine - Recruiting 5 years to 21 years.
- Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Relapsed and Refractory Pediatric Solid Tumors.
Metronomic Cyclophosphamide; Thalidomide

Malignant Solid Tumors Clinical Trial using Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

Baxter Healthcare Corporation - Recruiting 18 years or older.
- A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-MIF Antibody in Subjects With Malignant Solid Tumors.
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

Central Nervous System (CNS) Metastases, or Brain Metastases Clinical Trial using Topotecan; Temozolomide

The Methodist Hospital System - Recruiting 18 years to 79 years.
- Phase II Trial of Chemotherapy With Temozolomide in Combination With Topotecan for Central Nervous System (CNS) Metastasis of Solid Tumors.
Topotecan; Temozolomide

Solid Tumors, or Non-Hodgkin's Lymphoma Clinical Trial using Efavirenz

Institut Bergoni‚ - Recruiting 18 years to 80 years.
- Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure..
Efavirenz

Cholangiocarcinoma Clinical Trial using cytokine induced killer cells

Siriraj Hospital - Recruiting 8 years to 60 years.
- Phase 1 Study of The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells..
cytokine induced killer cells

Advanced Solid Tumors Clinical Trial using E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Eisai Inc. - Recruiting N/A or older.
- An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2).
E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Spinal Metastases Clinical Trial using hypofractionated 12x3 Gy + integrated boost 12x4 Gy; hypofractionated 10x3 Gy

University of Erlangen-Nrnberg Medical School - Recruiting 18 years or older.
- Efficacy of Dose Intensified Radiotherapy of Spinal Metastases of Solid Tumors by Dose Increased, Homogeneous Radiation of Vertebral Body and Simultaneous Application of Stereotactic Boost..
hypofractionated 12x3 Gy + integrated boost 12x4 Gy; hypofractionated 10x3 Gy

Children, Solid Tumors, or Metastases Clinical Trial using CELYVIR

Hospital Infantil Universitario Ni¤o Jes£s, Madrid, Spain - Recruiting 6 Months to 75 years.
- Phase 1 Trial of Celyvir in Children and Adults With Metastatic and Refractory Solid Tumors..
CELYVIR

Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of Clinical Trial using PD-0332991; pharmacological study

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer.
PD-0332991; pharmacological study

Non Small Cell Lung Cancer Clinical Trial using decitabine in combination with genistein

Uman Pharma - Recruiting 18 years to 75 years.
- A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects.
decitabine in combination with genistein

Cancer Patients With Solid Tumors Clinical Trial using YN968D1

Bukwang Pharmaceutical, Co., Ltd. - Recruiting 18 years or older.
- Evaluation of the Safety, Pharmacokinetics and Efficacy of Four Doses of YN968D1 in Subjects With Solid Tumors.
YN968D1

Solid Tumors Clinical Trial using OTX008

OncoEthix - Recruiting 18 years or older.
- A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors.
OTX008

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study

Eye Cancer Clinical Trial using dynamic contrast-enhanced magnetic resonance imaging

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- Dynamic Contrast Enhanced Magnetic Resonance Imaging for Non-Invasive Diagnostic Work-Up in Solid Tumors of the Eye and Orbit..
dynamic contrast-enhanced magnetic resonance imaging

Advanced Solid Tumors Clinical Trial using Tesetaxel

Genta Incorporated - Recruiting 20 years or older.
- A Phase I Study of Tesetaxel Administered Once Every 21 Days to Japanese Subjects With Advanced Solid Tumors.
Tesetaxel

Acute Leukemia, Myelodysplastic Syndrome, or Solid Tumors Clinical Trial using anti-thymocyte globulin; filgrastim; Total body irradiation; Fludarabine; cyclophosphamide; Tacrolimus; Mycophenolate mofetil; Rituximab

Asan Medical Center - Recruiting N/A to 21 years.
- HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3 Depletion for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors After Conditioning of TBI, Fludarabine, Cyclophosphamide and Antithymocyte Globulin.
anti-thymocyte globulin; filgrastim; Total body irradiation; Fludarabine; cyclophosphamide; Tacrolimus; Mycophenolate mofetil; Rituximab

Advanced Solid Tumors Clinical Trial using sapacitabine and seliciclib

Cyclacel Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors.
sapacitabine and seliciclib

Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Clinical Trial using CX-4945 oral formulation

Cylene Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma.
CX-4945 oral formulation

Advanced Solid Tumors Clinical Trial using M2ES 7.5mg; M2ES 15mg; M2ES 30mg; M2ES 60mg

Protgen Ltd - Recruiting 18 years to 65 years.
- Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors.
M2ES 7.5mg; M2ES 15mg; M2ES 30mg; M2ES 60mg

Solid Tumors Clinical Trial using Lapatinib and Sorafenib

Istituto Clinico Humanitas - Recruiting 18 years or older.
- Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors.
Lapatinib and Sorafenib

Neuroblastoma, Brain Tumors, or Solid Tumors Clinical Trial using Temozolomide/Hycamtin (Topotecan)

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 6 Months to 20 years.
- Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours.
Temozolomide/Hycamtin (Topotecan)

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using hydroxychloroquine; temozolomide; TdT-mediated dUTP nick end labeling assay; western blotting; electron microscopy; high performance liquid chromatography; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; mass spectrometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Hydroxychloroquine in Combination With Temozolomide in Patients With Advanced Solid Tumors.
hydroxychloroquine; temozolomide; TdT-mediated dUTP nick end labeling assay; western blotting; electron microscopy; high performance liquid chromatography; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; mass spectrometry; pharmacological study